info@PremierEndpoint.com (914) 315-9334

DARMSTADT, Germany and NEW YORK, USA, September 21, 2017 /PRNewswire/ — First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio’s previous accelerated approvals in the US and recent approval in Switzerland Approval based on data from Javelin Merkel 200 study including durable tumor response rate and duration of response Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: […]

3 Ways AI Is Changing Medicine
September 21, 2017

Recent developments in artificial intelligence (AI) are turning science fiction into science fact — and deep learning is at the heart of these advances. These AI systems have the ability to sift through scores of data, recognize patterns, and detect differences that might be imperceptible to humans. Some applications are already achieving remarkable results. One […]

VANCOUVER, British Columbia, and MENLO PARK, Calif., Sept. 18, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead […]

Pfizer just got some badly needed good news for its newly acquired cancer drug Xtandi. After watching sales sink right after it acquired the therapy and all of Medivation for $14 billion, researchers say the drug cleared the Phase III study for non-metastatic, castration resistant prostate cancer. And at least one prominent analyst says that’s […]

SILVER SPRING, Md., Sept. 14, 2017 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after […]

LISBON, PORTUGAL—Novo Nordisk’s combination med Xultophy, which marries its GLP-1 blockbuster Victoza and newest basal insulin Tresiba, became the latest diabetes med to show it could dampen risk factors for cardiovascular disease. The analysis, unveiled Wednesday at the European Association for the Study of Diabetes meeting in Lisbon, showed Xultophy patients had significantly lower systolic […]

Roche’s immuno-oncology drug Tecentriq took a surprising punch earlier this year when it failed a bladder cancer trial, putting a conditional approval in jeopardy. But the threat of losing FDA approval in bladder cancer has now passed. After recent discussions with the agency, the company expects Tecentriq’s accelerated approval “will be maintained,” a spokeswoman with […]

Top-10 oncology conferences to keep an eye on
September 12, 2017

With over 30 years of experience navigating the challenges associated with obtaining, analyzing, and translating complex clinical information for our oncology clients, we like to keep up to date with the latest biotech news and clinical trial data. We recommend you to keep an eye on the outcomes of the following top oncology conferences: ESMO […]

1 2 3 35